629 related articles for article (PubMed ID: 24655735)
1. Cytokine production profiles in chronic relapsing-remitting experimental autoimmune encephalomyelitis: IFN-γ and TNF-α are important participants in the first attack but not in the relapse.
Hidaka Y; Inaba Y; Matsuda K; Itoh M; Kaneyama T; Nakazawa Y; Koh CS; Ichikawa M
J Neurol Sci; 2014 May; 340(1-2):117-22. PubMed ID: 24655735
[TBL] [Abstract][Full Text] [Related]
2. Endothelin-1 overexpression exacerbate experimental allergic encephalomyelitis.
Guo Y; Chung SK; Siu CW; Kwan SC; Ho PW; Yeung PK; Chan KH
J Neuroimmunol; 2014 Nov; 276(1-2):64-70. PubMed ID: 25205217
[TBL] [Abstract][Full Text] [Related]
3. Anti-IL-16 therapy reduces CD4+ T-cell infiltration and improves paralysis and histopathology of relapsing EAE.
Skundric DS; Dai R; Zakarian VL; Bessert D; Skoff RP; Cruikshank WW; Kurjakovic Z
J Neurosci Res; 2005 Mar; 79(5):680-93. PubMed ID: 15682385
[TBL] [Abstract][Full Text] [Related]
4. Lentivirus-mediated estrogen receptor α overexpression in the central nervous system ameliorates experimental autoimmune encephalomyelitis in mice.
Hu X; Qin X
Int J Mol Med; 2013 May; 31(5):1209-21. PubMed ID: 23525227
[TBL] [Abstract][Full Text] [Related]
5. T cell-depleted splenocytes from mice pre-immunized with neuroantigen in incomplete Freund's adjuvant involved in protection from experimental autoimmune encephalomyelitis.
Zheng H; Zhang H; Liu F; Qi Y; Jiang H
Immunol Lett; 2014; 157(1-2):38-44. PubMed ID: 24220208
[TBL] [Abstract][Full Text] [Related]
6. Rescue from acute neuroinflammation by pharmacological chemokine-mediated deviation of leukocytes.
Berghmans N; Heremans H; Li S; Martens E; Matthys P; Sorokin L; Van Damme J; Opdenakker G
J Neuroinflammation; 2012 Oct; 9():243. PubMed ID: 23095573
[TBL] [Abstract][Full Text] [Related]
7. Chronic exercise confers neuroprotection in experimental autoimmune encephalomyelitis.
Pryor WM; Freeman KG; Larson RD; Edwards GL; White LJ
J Neurosci Res; 2015 May; 93(5):697-706. PubMed ID: 25510644
[TBL] [Abstract][Full Text] [Related]
8. Systemic administration of orexin A ameliorates established experimental autoimmune encephalomyelitis by diminishing neuroinflammation.
Becquet L; Abad C; Leclercq M; Miel C; Jean L; Riou G; Couvineau A; Boyer O; Tan YV
J Neuroinflammation; 2019 Mar; 16(1):64. PubMed ID: 30894198
[TBL] [Abstract][Full Text] [Related]
9. VPAC1 receptor (Vipr1)-deficient mice exhibit ameliorated experimental autoimmune encephalomyelitis, with specific deficits in the effector stage.
Abad C; Jayaram B; Becquet L; Wang Y; O'Dorisio MS; Waschek JA; Tan YV
J Neuroinflammation; 2016 Jun; 13(1):169. PubMed ID: 27357191
[TBL] [Abstract][Full Text] [Related]
10. IL-12Rβ2 has a protective role in relapsing-remitting experimental autoimmune encephalomyelitis.
Xie C; Ciric B; Yu S; Zhang GX; Rostami A
J Neuroimmunol; 2016 Feb; 291():59-69. PubMed ID: 26857496
[TBL] [Abstract][Full Text] [Related]
11. Characterization of relapsing-remitting and chronic forms of experimental autoimmune encephalomyelitis in C57BL/6 mice.
Berard JL; Wolak K; Fournier S; David S
Glia; 2010 Mar; 58(4):434-45. PubMed ID: 19780195
[TBL] [Abstract][Full Text] [Related]
12. Changes in nociceptive sensitivity and object recognition in experimental autoimmune encephalomyelitis (EAE).
Olechowski CJ; Tenorio G; Sauve Y; Kerr BJ
Exp Neurol; 2013 Mar; 241():113-21. PubMed ID: 23291347
[TBL] [Abstract][Full Text] [Related]
13. The contribution of the acute phase response to the pathogenesis of relapse in chronic-relapsing experimental autoimmune encephalitis models of multiple sclerosis.
Mardiguian S; Ladds E; Turner R; Shepherd H; Campbell SJ; Anthony DC
J Neuroinflammation; 2017 Sep; 14(1):196. PubMed ID: 28964257
[TBL] [Abstract][Full Text] [Related]
14. The MAO inhibitor phenelzine can improve functional outcomes in mice with established clinical signs in experimental autoimmune encephalomyelitis (EAE).
Benson CA; Wong G; Tenorio G; Baker GB; Kerr BJ
Behav Brain Res; 2013 Sep; 252():302-11. PubMed ID: 23777648
[TBL] [Abstract][Full Text] [Related]
15. Differential brain and spinal cord cytokine and BDNF levels in experimental autoimmune encephalomyelitis are modulated by prior and regular exercise.
Bernardes D; Oliveira-Lima OC; Silva TV; Faraco CC; Leite HR; Juliano MA; Santos DM; Bethea JR; Brambilla R; Orian JM; Arantes RM; Carvalho-Tavares J
J Neuroimmunol; 2013 Nov; 264(1-2):24-34. PubMed ID: 24054000
[TBL] [Abstract][Full Text] [Related]
16. Human mesenchymal stem cells upregulate CD1dCD5(+) regulatory B cells in experimental autoimmune encephalomyelitis.
Guo Y; Chan KH; Lai WH; Siu CW; Kwan SC; Tse HF; Wing-Lok Ho P; Wing-Man Ho J
Neuroimmunomodulation; 2013; 20(5):294-303. PubMed ID: 23899693
[TBL] [Abstract][Full Text] [Related]
17. Relapsing and remitting experimental allergic encephalomyelitis: a focused response to the encephalitogenic peptide rather than epitope spread.
Takács K; Chandler P; Altmann DM
Eur J Immunol; 1997 Nov; 27(11):2927-34. PubMed ID: 9394820
[TBL] [Abstract][Full Text] [Related]
18. Dynamic changes in meningeal inflammation correspond to clinical exacerbations in a murine model of relapsing-remitting multiple sclerosis.
Walker-Caulfield ME; Hatfield JK; Brown MA
J Neuroimmunol; 2015 Jan; 278():112-22. PubMed ID: 25595260
[TBL] [Abstract][Full Text] [Related]
19. Differential expression of SOCS1 in macrophages in relapsing-remitting and chronic EAE and its role in disease severity.
Berard JL; Kerr BJ; Johnson HM; David S
Glia; 2010 Nov; 58(15):1816-26. PubMed ID: 20645407
[TBL] [Abstract][Full Text] [Related]
20. Genetic inactivation of the adenosine A(2A) receptor exacerbates brain damage in mice with experimental autoimmune encephalomyelitis.
Yao SQ; Li ZZ; Huang QY; Li F; Wang ZW; Augusto E; He JC; Wang XT; Chen JF; Zheng RY
J Neurochem; 2012 Oct; 123(1):100-12. PubMed ID: 22639925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
